---
layout: default
title: Bevacizumab
description: "Bevacizumab çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 33
evidence_level: L5
indication_count: 10
---

# Bevacizumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Bevacizumabï¼šå¾å¤šç¨®ç™Œç—‡åˆ°æœƒå­è…«ç˜¤

## ä¸€å¥è©±ç¸½çµ
<p class="key-answer" data-question="Bevacizumab å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Bevacizumab åŸç‚ºæŠ—è¡€ç®¡æ–°ç”Ÿçš„ç™Œç—‡æ¨™é¶è—¥ç‰©ï¼Œç”¨æ–¼è½‰ç§»æ€§å¤§è…¸ç›´è…¸ç™Œã€è‚ºç™Œã€åµå·¢ç™Œç­‰å¤šç¨®æƒ¡æ€§è…«ç˜¤ï¼ŒTxGNN é æ¸¬å…¶å¯èƒ½å°æœƒå­è…«ç˜¤(epiglottis neoplasm)æœ‰æ²»ç™‚æ½›åŠ›ã€‚
</p>


## å¿«é€Ÿç¸½è¦½
| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | è½‰ç§»æ€§å¤§è…¸ç›´è…¸ç™Œã€ä¹³ç™Œã€éå°ç´°èƒè‚ºç™Œã€åµå·¢ç™Œã€å­å®®é ¸ç™Œã€ç¥ç¶“è† æ¯ç´°èƒç˜¤ç­‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | epiglottis neoplasmã€benign neoplasm of tongueã€tumor of testis and paratestisã€benign neoplasm of hypopharynxã€benign neoplasm of floor of mouthã€cervical neuroblastomaã€cystic neoplasmã€nasal cavity inverting papillomaã€mesenchymomaã€schwannoma of jugular foramen |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.90% |
| è­‰æ“šç­‰ç´š | L5 (åƒ…é æ¸¬) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ (Avastinã€MVASIã€ABEVMYã€Vegzelmaç­‰) |
| å»ºè­°æ±ºç­– | Explore |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. epiglottis neoplasm</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Bevacizumab æ˜¯ä¸€ç¨®äººæºåŒ–å–®æ ªæŠ—é«”ï¼Œé€éçµåˆè¡€ç®¡å…§çš®ç”Ÿé•·å› å­(VEGF)ä¾†æŠ‘åˆ¶è…«ç˜¤è¡€ç®¡æ–°ç”Ÿã€‚å…¶ä½œç”¨æ©Ÿè½‰å…·æœ‰å»£æ³›çš„æŠ—è…«ç˜¤æ´»æ€§ï¼š

1. **è¡€ç®¡æ–°ç”ŸæŠ‘åˆ¶**ï¼šé˜»æ–· VEGF è¨Šè™Ÿå‚³å°ï¼Œæ¸›å°‘è…«ç˜¤è¡€ç®¡å½¢æˆ
2. **é ­é ¸éƒ¨ç™Œç—‡ç¶“é©—**ï¼šå·²æ ¸å‡†ç”¨æ–¼é ­é ¸éƒ¨é±—ç‹€ç´°èƒç™Œ(HNSCC)çš„æ²»ç™‚
3. **è§£å‰–ä½ç½®ç›¸é—œ**ï¼šæœƒå­å±¬æ–¼é ­é ¸éƒ¨å€åŸŸï¼Œèˆ‡å·²æ ¸å‡†é©æ‡‰ç—‡çš„é ­é ¸éƒ¨ç™Œç—‡æœ‰ç›¸ä¼¼çš„è¡€ç®¡ç”Ÿæˆç‰¹æ€§

æœƒå­è…«ç˜¤é›–ç‚ºç½•è¦‹ç–¾ç—…ï¼Œä½†å…¶è¡€ç®¡ä¾›æ‡‰ç‰¹æ€§èˆ‡å…¶ä»–é ­é ¸éƒ¨è…«ç˜¤ç›¸ä¼¼ï¼Œç†è«–ä¸Šå¯èƒ½å°æŠ—è¡€ç®¡æ–°ç”Ÿæ²»ç™‚æœ‰åæ‡‰ã€‚

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡é‡å° bevacizumab æ²»ç™‚æœƒå­è…«ç˜¤çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

ç„¶è€Œï¼Œç›¸é—œçš„é ­é ¸éƒ¨ç™Œç—‡è‡¨åºŠè©¦é©—åŒ…æ‹¬ï¼š
- **NCT01552434**ï¼šPhase I è©¦é©—ï¼Œè©•ä¼° bevacizumab èˆ‡ temsirolimus åœ¨æ™šæœŸæƒ¡æ€§è…«ç˜¤çš„æ‡‰ç”¨
- **NCT00023959**ï¼šPhase I è©¦é©—ï¼Œè©•ä¼° bevacizumab åˆä½µåŒ–æ”¾ç™‚æ²»ç™‚é å¾Œä¸è‰¯çš„é ­é ¸éƒ¨ç™Œç—‡

### ç›¸é—œæ–‡ç»

PubMed æª¢ç´¢ç™¼ç¾æœ‰é—œæ–¼ bevacizumab åœ¨é ­é ¸éƒ¨ç™Œç—‡çš„è‡¨åºŠå‰ç ”ç©¶ï¼š

- Bozec A ç­‰äºº(2008)ç™¼è¡¨æ–¼ *British Journal of Cancer*ï¼Œè­‰å¯¦ bevacizumab åˆä½µ erlotinib åŠæ”¾ç™‚åœ¨é ­é ¸éƒ¨è…«ç˜¤æ­£ä½æ¨¡å¼ä¸­çš„æŠ—è…«ç˜¤æ•ˆæœ
- å¤šç¯‡ç ”ç©¶æ”¯æŒæŠ— VEGF ç™‚æ³•åœ¨é ­é ¸éƒ¨è…«ç˜¤çš„æ‡‰ç”¨æ½›åŠ›

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. benign neoplasm of tongue</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.90%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. tumor of testis and paratestis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.90%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. benign neoplasm of hypopharynx</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.90%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. benign neoplasm of floor of mouth</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.90%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. cervical neuroblastoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.89%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. cystic neoplasm</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.89%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. nasal cavity inverting papilloma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.89%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. mesenchymoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.89%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. schwannoma of jugular foramen</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.89%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š
Bevacizumab åœ¨å°ç£æœ‰å¤šé …è—¥å“è¨±å¯è­‰ï¼š
- **Avastin (ç™Œæ€åœ)** - ç¾…æ°
- **MVASI** - å®‰é€²
- **ABEVMY** - ä¸‰æ˜Ÿç”ŸæŠ€
- **Vegzelma (è‰¾æ³•æ–½)** - ä¿¡æ±

æ ¸å‡†é©æ‡‰ç—‡æ¶µè“‹ï¼š
- è½‰ç§»æ€§å¤§è…¸ç›´è…¸ç™Œ
- è½‰ç§»æ€§ä¹³ç™Œ(HER2 é™°æ€§)
- éå°ç´°èƒè‚ºç™Œ
- ç¥ç¶“è† æ¯ç´°èƒç˜¤
- åµå·¢ä¸Šçš®ç´°èƒç™Œ
- å­å®®é ¸ç™Œ

## å®‰å…¨æ€§è€ƒé‡
### å¸¸è¦‹å‰¯ä½œç”¨
- é«˜è¡€å£“
- è›‹ç™½å°¿
- å‡ºè¡€äº‹ä»¶
- å‚·å£ç™’åˆå»¶é²

### åš´é‡è­¦èª
- èƒƒè…¸é“ç©¿å­”é¢¨éšª
- å‹•è„ˆè¡€æ “æ “å¡äº‹ä»¶
- éœ€ç›£æ¸¬è¡€å£“åŠè›‹ç™½å°¿

### è—¥ç‰©äº¤äº’ä½œç”¨
èˆ‡å…¶ä»–æŠ—ç™Œè—¥ç‰©ä½µç”¨æ™‚éœ€æ³¨æ„éª¨é«“æŠ‘åˆ¶åŠ æˆæ•ˆæ‡‰ã€‚


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Hemorrhage** ğŸŸ¡ Moderate
- Bevacizumab impairs wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Bevacizumab should not be started for at least 28 days after surgery and until the wound is fully healed.  Disc...

**é«˜è¡€å£“ (Hypertension)** ğŸŸ¡ Moderate
- Inhibitors of vascular endothelial growth factor receptors (VEGFR) have been associated with severe increases in blood pressure.  Therapy with these agents should be administered cautiously in patients with preexisting hypertension.  Blood pressure s...

**Posterior Leukoencephalopathy Syndrome** ğŸŸ¡ Moderate
- Posterior Reversible Encephalopathy Syndrome (PRES) has been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR) in clinical studies.  PRES is a neurological disorder which can present with headache, seizure, l...

**Proteinuria** ğŸŸ¡ Moderate
- The incidence and severity of proteinuria is increased in patients taking inhibitors of vascular endothelial growth factor receptors (VEGFR).  Therapy with these agents should be administered cautiously in patients with renal dysfunction.  Monitoring...

**Thromboembolism** ğŸŸ¡ Moderate
- Venous and arterial thromboembolic events (VTE and ATE), some fatal, have been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR).  Caution is recommended when using these agents in patients with a reported hi...

*å¦æœ‰ 2 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥
**è­‰æ“šç­‰ç´š**ï¼šL5 (åƒ… TxGNN é æ¸¬ï¼Œç„¡è‡¨åºŠè­‰æ“š)

**å»ºè­°**ï¼š
1. æœƒå­è…«ç˜¤ç‚ºç½•è¦‹ç–¾ç—…ï¼Œç›®å‰ç„¡æ¨™æº–æ²»ç™‚æ–¹æ¡ˆæ™‚å¯è€ƒæ…®æ¢ç´¢æ€§ä½¿ç”¨
2. å»ºè­°å„ªå…ˆåƒè€ƒé ­é ¸éƒ¨é±—ç‹€ç´°èƒç™Œçš„ bevacizumab ä½¿ç”¨ç¶“é©—
3. è‹¥è€ƒæ…®è‡¨åºŠæ‡‰ç”¨ï¼Œæ‡‰åœ¨è…«ç˜¤å°ˆç§‘é†«å¸«æŒ‡å°ä¸‹é€²è¡Œ

**ä¸‹ä¸€æ­¥ç ”ç©¶æ–¹å‘**ï¼š
- å›é¡§æ€§åˆ†æé ­é ¸éƒ¨ç™Œç—‡ç—…ä¾‹ä¸­æœƒå­å—ç´¯çš„æ²»ç™‚åæ‡‰
- è€ƒæ…®å€‹æ¡ˆå ±å‘Šæˆ–å°è¦æ¨¡è‡¨åºŠè©¦é©—è©•ä¼°å¯è¡Œæ€§


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Voriconazole]({{ "/drugs/voriconazole/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Disopyramide]({{ "/drugs/disopyramide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Trifluoperazine]({{ "/drugs/trifluoperazine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Povidone]({{ "/drugs/povidone/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Etanercept]({{ "/drugs/etanercept/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Bevacizumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/bevacizumab/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_bevacizumab,
  title = {Bevacizumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/bevacizumab/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
